Seven intensive care patients were sedated with prolonged infusion of midazolam. One patient received a continuous infusion of midazolam for the treatment of status epilepticus. A bolus injection of 5 mg was administered, followed by infusion of 4-14 mg/hour depending on the required level of sedation. The length of infusion varied between 80 and 360 hours. The plasma concentrations of the midazolam during infusion were between 500-1000 ng/ml. All the patients were adequately sedated. The plasma elimination half-life of midazolam and its main metabolite, 1-0H-midazolam glucuronide, after stopping the infusion variedfrom 4-12 hours.
We initiated an investigation of a shortacting benzodiazepine, midazolam, as it was anticipated that this drug would not show prolonged recovery times. We report here on the pilot study to evaluate the clinical efficacy and pharmacokinetics of midazolam, and its metabolites, during and after long-term infusion.
PATIENTS AND METHODS Eight patients were studied (four women and four men). Patients in the study group were all critically ill patients (Table 1) . Each patient received mechanical ventilation.
Drug administration
Midazolam was administered in a loading dose of 5 mg followed by a continuous infusion of 4-14 mglhr IV, the dose being adapted when the patient was not adequately sedated. In one patient, treated for a status epilepticus, a loading dose of 120 mg' was given, followed by a continuous infusion of 30 mglhr IV. In six out of eight patients, nicomorphine was administered for postoperative 'pain relief. The nicomorphine was given in a continuous infusion of 2-3 mglhr IV or in a bolus injection of 5 mg IV every six hours.
Parameters of efficacy
The degree of sedation was measured on a three-point scale. 1 sleepy but easily arousable 2 = asleep but not easily arousable 3 = unable to communicate Furthermore, a rating on a three-point scale (good, acceptable, or poor) was done by the nurse for two parameters: -acceptance of the endotracheal tube by the patient; -co-operation of the patient with endotracheal suction.
Pharmacokinetics
Blood and urine samples were collected every six hours during the infusion period and for a period of 48 hours after discontinuation of the infusion.
Sample preparation
A small volume of plasma or urine (0.2 ml) was mixed with 0.2 ml of a saturated solution of sodium phosphate and 3.0 ml dichloromethane. The solution was mixed for one minute and centrifuged for seven minutes Porto-caval shunt at 3.500 r.p.m. The organic layer was transferred and evaporated to dryness under a stream of air at 50°C. An aliquot, 0.2 ml, of methanol and water (80:20 v/v) was added to the residue and 50 III was injected onto the column.
Deglucuronidation of the samples
Plasma (0.2 ml) was incubated with 200 III P-glucuronidase (Sigma, St. Louis, U.S.A., 10,000 U.ml-I in acetate buffer (pH 5, 0.2M) for 12 hours, and 400 III of a saturated solution of sodium phosphate was added. The mixture was extracted with dichloromethane, mixed, centrifuged, evaporated to dryness and prepared for injection onto the column as described above.
Urine (0.1 ml) was incubated with 100 III Pglucuronidase for 12 hours. Therafter, 200 III of a saturated solution of sodium phosphate was added. The same procedure was then carried out as stated above, with exception that the residue was dissolved in methanol 1.0 ml and water.
Recovery
The recovery of the extraction procedure was 80% for midazolam and 85% for its hydroxymetabolite over the concentration range measured. The inter-assay variation coefficient at a level of 300 ng/ml was 5% for midazolam and 8% for its hydroxymetabolite.
The calibration curves were linear for the concentration range measured (r = 0.997).
Apparatus
A Millipore Waters Associates, Model 510 High-Pressure Liquid Chromatography (HPLC) was equipped with a variable wave length UV detector Model 481 (Waters). The detector was connected to an integrator (Shimadzu CR-3A). A stainless steel column, 250 mm (length) by 4.6 mm ID packed with Hypersil 5 ods (Chrompack, The Netherlands), was used. The injection loop was 50 Ill. Detection of midazolam and metabolites was effected at 229 nm. The detection limit was 20 nglml.
Solvent
The solvent was a mixture of phosphate buffer pH 7.4, methanol, water and acetonitrile (10:60:29: 1 v/v). The flow rate was 1.6 ml/min at a presssure of 22.78 MP.
Drugs
Midazolam, I-hydroxymethylmidazolam, 4-hydroxy-midazolam, and I-hydroxy methyl-4-hydroxy-midazolam, were obtained from Hoffmann-La Roche (Mijdrecht, The Netherlands).
Pharmacokinetic analysis
Half-life, regression lines and standard deviations were calculated according to standard statistical procedures with an HP 41 calculator (Hewlett Packard).
Renal clearance
The renal clearance value of midazolam, I-hydroxymethylmidazolam, and I-hydroxymethyl-midazolam-glucuronide, were calculated for each patient with the total amount of each excreted in the urine, divided by the area under the plasma concentration curve (AUC).
Total body clearance
The total body clearance of midazolam was calculated from the total dose of midazolam administered, divided by the plasma AUC.
RESULTS
The patient characteristics are summarised in Table 1 . All patients were mechanically ventilated. Liver function tests (SGOT, SGPT) were normal in all patients. Seven out of eight patients had normal creatinine clearances. In patient 2, clearance was 25 mllmin.
The total dose of midazolam was between 365 and 3222 mg at rates varying from 4 to 14 mglhr to achieve the desired degree of sedation. All patients were 'asleep but not easily arousable' to 'unable to communicate with'.
The plasma levels of midazolam producing the desired hypnotic/sedative effect were approximately 1000 ng/ml with high interindi vid ual variability. Large interindividual variation was also found in the AUC rate midazolamll-hydroxy- midazolam glucuronide and in total body and renal clearance of midazolam (Table 2) .
In five patients plasma concentrations of midazolam and I-hydroxymidazolam glucuronide remained fairly well constant during continuous infusion at constant rates.
Increasing plasma concentrations of midazolam andlor I-hydroxy-midazolam glucuronide during constant rate infusion were found in two patients (numbers 2 and 6 of Table 1 and 2).
In patient 1, plasma concentrations of midazolam and I-hydroxy-midazolam glucuronide decreased during constant infusion. Plasma elimination half-lives of midazolam and I-hydroxymidazolam glucuronide after discontinuation of the infusion were identical and varied between 4 and 12 hours. This was consistent with rapid recovery from sedation, except in patient 8.
The recovery in the urine of midazolam and metabolites varied from 5% to 72% of the administered dose almost exclusively as I-hydroxymidazolam glucuronide.
DISCUSSION
Until recently, diazepam and chlorazepate were the agents of choice for sedation of ICU patients. 1 Both drugs and their metabolites however, have a long elimination half-life, and their main metabolite (desmethyldiazepam) is also hypnotically active. Both of these produce prolonged recovery times unless the dosage is kept to a minimum. In the critically ill patient the effects may be unexpectedly prolonged. The recently introduced water-soluble· imidazobenzodiazepine midazolam with a short halflife appears to offer an alternative to diazepam or chlorazepate for sedation in an ICU. Midazolam has a short T 1/2 after a single-bolus administration,2-4 and after discontinuation of a continuous infusion. 5 ,6 One report, however, described a prolonged sedation period after a repeated and prolonged therapy with midazolam. 7 In our study the elimination half-life varied from 4-12 hours and no prolonged sedation was observed. With a continuous infusion of midazolam, the amount of drug necessary for Anaesthesia and Intensive Care. Vol. 15. No. 4, November. 1987 well-defined plasma levels, C.q. sedation (rated on a three-point scale) can be minimised as compared with other optimised dosage regimens such as repetitive bolus injections. 5 . 6 . 8 In the present study, plasma levels producing a hypnotic effect are approximately 1000 ng/m!. This is much higher than the values reported in studies with healthy volunteers 4 and in patients during anaesthesia (60-100 ng/ml).
Large inter-individual variations are found in the total clearance of midazolam and in the AUC ratio midazolam/l-0H-midazolamglucuronide during the long-term infusion ( Table 2 ). This finding may be explained by the combined variations in hepatic clearance of the drug, reduced liver perfusion, secondary to pharmacokinetic variation, reduced kidney function, or an interaction with an enzyme-stimulating drug. 7 The influence of an impaired organ-function on the clearance of a drug is difficult to specify in intensive care patients. Circulation, oxygenation, metabolic conditions (electrolytes, albumin) can all be disturbed and this may be difficult to quantify. Another problem is that one intensive care patient is not comparable with another. The results from pharmacokinetic studies in seriously ill patients should therefore be evaluated on an individual basis.
In conclusion, the present study shows that long-term infusion of midazolam produces an adequate level of sedation at infusion rates varying from 4-14 mg/hr. The elimination half-life varies from 4-12 hours, no prolonged sedation is observed in seven of the eight patients. Large inter-individual variations were shown in total body (= metabolic) clearance of midazolam and in the ratio midazolam: 1-0H-midazolam-glucuronide. Further studies must be carried out to elucidate the effects of multiple organ failure on the rate of metabolism and renal clearance of midazolam and its hydroxy metabolites.
